Search Results
PRIME-HCC: ipilimumab and nivolumab in liver cancer
Considerations for Using Nivolumab in Advanced HCC
Cancer Immunotherapy with Nivolumab Plus Ipilimumab Vs. Chemotherapy: Insights from CheckMate 227
Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial
Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC
The use of immunotherapy in HCC – In depth subgroup analyses and challenges
Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook
Benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma
Ipilimumab Combined With Nivolumab for Patients With Melanoma
Combining nivolumab and ipilimumab in patients with resected stage IV melanoma
Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver Cancer
Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC